{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:58:59Z","timestamp":1787990339886,"version":"build-2784847793"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,7]],"date-time":"2015-01-07T00:00:00Z","timestamp":1420588800000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100015237","name":"The Medicines Company","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100015237","name":"The Medicines Company","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol-Myers Squibb\/Sanofi-Aventis"},{"name":"Lilly\/Daiichi Sankyo"},{"DOI":"10.13039\/100015237","name":"The Medicines Company","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.jacc.2013.09.027","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T17:00:28Z","timestamp":1381942828000},"page":"15-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Reduction in Cardiac Mortality With Bivalirudin in Patients With and Without Major Bleeding"],"prefix":"10.1016","volume":"63","author":[{"given":"Gregg W.","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymios N.","family":"Deliargyris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Prats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2013.09.027_bib1","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.09.027_bib2","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(11)60764-2","article-title":"Heparin plus a glycoprotein IIb\/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial","volume":"377","author":"Stone","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.09.027_bib3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.amjcard.2012.03.051","article-title":"Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention","volume":"110","author":"Bertrand","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2013.09.027_bib4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehp437","article-title":"Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention","volume":"31","author":"Rassen","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.09.027_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/CIRCOUTCOMES.111.961938","article-title":"Bivalirudin therapy is\u00a0associated with improved clinical and economic outcomes in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database","volume":"5","author":"Pinto","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2013.09.027_bib6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1540-8183.2012.00720.x","article-title":"Comparative effectiveness analysis of anticoagulant strategies in a large observational database of percutaneous coronary interventions","volume":"25","author":"Wise","year":"2012","journal-title":"J\u00a0Interv Cardiol"},{"key":"10.1016\/j.jacc.2013.09.027_bib7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2013.09.027_bib8","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.09.027_bib9","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention","volume":"359","author":"Kastrati","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.09.027_bib10","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","article-title":"Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction","volume":"365","author":"Kastrati","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.09.027_bib11","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1001\/jama.2010.708","article-title":"Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention","volume":"303","author":"Marso","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2013.09.027_bib12","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jama.292.13.1555","article-title":"Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes","volume":"292","author":"Rao","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2013.09.027_bib13","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.09.027_bib14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jcin.2010.10.011","article-title":"Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention","volume":"4","author":"Verheugt","year":"2011","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2013.09.027_bib15","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A\u00a0risk score to predict bleeding in patients with acute coronary syndromes","volume":"55","author":"Mehran","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.09.027_bib16","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.amjcard.2005.04.005","article-title":"Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction","volume":"96","author":"Nikolsky","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2013.09.027_bib17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1067\/mhj.2000.106615","article-title":"Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb\/IIIa blockade","volume":"140","author":"Kereiakes","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2013.09.027_bib18","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1161\/01.CIR.0000127867.41621.85","article-title":"Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting","volume":"109","author":"Merlini","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.09.027_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.298.1.37-b","article-title":"Timing of glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes","volume":"298","author":"Stone","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2013.09.027_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2040620712443537","article-title":"Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia","volume":"3","author":"Bakchoul","year":"2012","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jacc.2013.09.027_bib21","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0735-1097(03)00920-3","article-title":"The incidence, predictors, and outcomes of early reinfarction after primary angioplasty for acute myocardial infarction","volume":"42","author":"Kernis","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.09.027_bib22","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.ahj.2005.06.047","article-title":"Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction","volume":"151","author":"De Luca","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2013.09.027_bib23","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0002-9440(10)64824-9","article-title":"Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation","volume":"157","author":"Erlich","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jacc.2013.09.027_bib24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/j.jvca.2006.02.028","article-title":"Inhibition of thrombin during reperfusion improves immediate postischemic myocardial function and modulates apoptosis in a porcine model of cardiopulmonary bypass","volume":"21","author":"Jormalainen","year":"2007","journal-title":"J\u00a0Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jacc.2013.09.027_bib25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.yjmcc.2005.03.005","article-title":"Thrombin increases cardiomyocyte acute cell death after ischemia and reperfusion","volume":"39","author":"Mirabet","year":"2005","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.jacc.2013.09.027_bib26","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.107.692764","article-title":"Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy","volume":"116","author":"Pawlinski","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.09.027_bib27","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1124\/jpet.107.133595","article-title":"Inhibiting protease-activated receptor 4 limits myocardial ischemia\/reperfusion injury in rat hearts by unmasking adenosine signaling","volume":"324","author":"Strande","year":"2008","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jacc.2013.09.027_bib28","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/TP.0b013e3181d72117","article-title":"Thrombin inhibition during kidney ischemia-reperfusion reduces chronic graft inflammation and tubular atrophy","volume":"90","author":"Thuillier","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.jacc.2013.09.027_bib29","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.athoracsur.2010.02.068","article-title":"Synergistic protection in lung ischemia-reperfusion injury with calcineurin and thrombin inhibition","volume":"89","author":"McCourtie","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2013.09.027_bib30","doi-asserted-by":"crossref","first-page":"e34344","DOI":"10.1371\/journal.pone.0034344","article-title":"Distinct effects of unfractionated heparin versus bivalirudin on circulating angiogenic peptides","volume":"7","author":"Kapur","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2013.09.027_bib31","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jacc.2013.01.048","article-title":"Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA-STEMI trial","volume":"61","author":"Eitel","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.09.027_bib32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.thromres.2011.10.020","article-title":"Controlled reperfusion with intravenous bivalirudin and intracoronary abciximab combination therapy in the porcine myocardial infarction model","volume":"130","author":"Buszman","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2013.09.027_bib33","first-page":"1083","article-title":"Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the HORIZONS-AMI CMRI substudy","volume":"79","author":"W\u00f6hrle","year":"2012","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2013.09.027_bib34","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.jacc.2005.12.077","article-title":"A\u00a0randomized trial to evaluate the relative protection against post-PCI microvascular dysfunction, ischemia and inflammation among anti-platelet and antithombotic agents: the PROTECT-TIMI 30 trial","volume":"47","author":"Gibson","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.09.027_bib35","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ahj.2011.08.022","article-title":"Relationship between angiographic dynamic and densitometric assessment of myocardial reperfusion and survival in patients with acute myocardial infarction treated with primary percutaneous coronary intervention","volume":"162","author":"Brener","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2013.09.027_bib36","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCINTERVENTIONS.112.000142","article-title":"Relationship between ST-segment recovery and clinical outcomes after primary percutaneous coronary intervention: the HORIZONS-AMI ECG substudy report","volume":"6","author":"Farkouh","year":"2013","journal-title":"Circ Cardiovasc Interv"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713055356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713055356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:04:12Z","timestamp":1760015052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109713055356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0735109713055356"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2013.09.027","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction in Cardiac Mortality With Bivalirudin in Patients With and Without Major Bleeding","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2013.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}